Last mentioned: Mar 20, 2026
Across the most recent 4 stories covering Food and Drug Administration (FDA) — 25% positive, 25% negative, 50% neutral sentiment, averaging 6.8/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ALJ Hearing on Marijuana Rescheduling
A seven-day administrative hearing is held in Arlington, Virginia, debating whether marijuana has a 'currently accepted medical use' without MMJ's testimony or evidence.
DEA Excludes MMJ from Rescheduling Hearing
The DEA denies MMJ International Holdings' request to participate in the upcoming administrative hearing, asserting that its evidence raises only questions of law.
Federal Appeals Court Bans Mailing Mifepristone
A federal appeals court made it illegal to mail mifepristone, a key medication abortion pill, threatening telehealth access.
Supreme Court Issues Stay on Mifepristone Ban
The Supreme Court stayed the appeals court ruling, allowing mailing to continue while the legal challenge proceeds.
Legal Challenges
Expected filing of lawsuits by environmental groups to block the relaxation of standards.
EPA Rollback Proposal
The EPA announces moves to weaken the previously established pollution limits.
Industry Petitions
Medical tech groups and the FDA raise alarms about potential device shortages due to facility closures.
Strict Standards Finalized
EPA issues a rule requiring a 90% reduction in EtO emissions from sterilization plants.
Supreme Court Overturns Roe v. Wade in Dobbs Decision
The landmark ruling eliminated the constitutional right to abortion, allowing states to enact bans.
MMJ International Holdings alleges the DEA violated administrative law by excluding it from marijuana rescheduling hearings, despite spending $10 million on FDA-pathway development. The exclusion raises due process and APA concerns that could imperil the final rule.
Source: saltlakecitysun.com · memphissun.com
Despite state bans, U.S. abortions nearly doubled, fueled by telehealth pill delivery across state lines. This exposes legal tensions between state authority, FDA preemption, and 19th-century obscenity statutes.
The Environmental Protection Agency has proposed a relaxation of pollution standards for chemicals used in medical equipment sterilization, specifically targeting Ethylene Oxide (EtO). This move attempts to balance carcinogenic health risks against the critical need to maintain the national medical device supply chain.
Source: winnipegfreepress.com · kten.com
The U.S. Food and Drug Administration is implementing a performance-based bonus structure to reward staffers who complete drug reviews ahead of schedule. This initiative aims to accelerate the therapeutic pipeline but has sparked immediate debate over the potential impact on safety standards and regulatory rigor.
Source: sbsun.com · timesargus.com
This page surfaces every story mentioning Food and Drug Administration (FDA) across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Food and Drug Administration (FDA) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |